Ethos Technologies Inc. Class A Common Stock

Day range

$41.51 – $43.99

Open

$43.34

Prev close

$43.10

Volume

320.24K

Market cap

$2.8B

Shares out

64.98M

• Guidance issuance or updateSep 16, 2026

  The Company does not expect any material impact from the TruStage incident on its Q3 2026 financials. Any impact of the incident was factored into the Company's Q3 2026 financial guidance issued on August 3, 2026.

• Share repurchase programAug 3, 2026

  On August 2, 2026, the Board of Directors of the Company authorized a share repurchase program of up to $100 million of the Company's outstanding Class A common stock. Repurchases may be effected, from time to time, either on the open market (including pre-set trading plans), in privately negotiated transactions, and other transactions in accordance with applicable securities laws.

• Charter amendmentFeb 2, 2026

  On January 30, 2026, the Company filed an amended and restated certificate of incorporation (the "Restated Certificate") with the Secretary of State of the State of Delaware in connection with the closing of the IPO. The Company's board of directors (the "Board") and the Company's stockholders previously approved the Restated Certificate to be effective upon the closing of the IPO.

• Listing deficiency noticeDec 5, 2025

  On December 4, 2025, aTyr Pharma, Inc. (the "Company") received a deficiency notice (the "Notice") from the listing qualifications staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for the last 30 consecutive business days preceding the date of the Notice, the bid price of the Company's common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2).

• Clinical trial resultsSep 15, 2025

  On September 15, 2025, aTyr Pharma, Inc. (the "Company") announced topline results from its Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis... The study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid ("OCS") dose at week 48. The change from baseline in mean daily OCS dose reduced to an average of 2.79 mg for 5.0 mg/kg efzofitimod vs 3.52 mg for placebo (p=0.3313).

Days to cover

2.0

Short interest

3.71M

Avg volume

1.83M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Ethos Chief Underwriter Nichole Myers Shares Why So Many Americans Are Still Waiting to Get Life Insurance on YourUpdateTV
  positiveGlobeNewswire Inc.· Sep 4, 2026
• aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
  GlobeNewswire Inc.· Jun 3, 2024
• aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  GlobeNewswire Inc.· May 24, 2024
• Wall Street Breakfast: The Week Ahead
  Seeking Alpha· May 19, 2024
• aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
  GlobeNewswire Inc.· May 15, 2024